Current stock page

Stock Analysis

Cigna Corporation (CI) Stock Analysis

Cigna Corporation (CI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

CI Stock Analysis Summary

Cigna Corporation (CI) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 84/100. Quality is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Oct 21, 2026 · Market-close data

CI at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$304.37
AIQ Score62/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$74.8B
P/E Ratio (TTM)11.67
Forward P/E—
EPS (quarter ended 2026-06-30)$6.29
Revenue (quarter ended 2026-06-30)$71.67B
Dividend Yield (TTM)2.17%
Beta0.32
Volume1.3M
52-week range$239.51-$311.34
RSI 1486.07
50-Day SMA$280.41
200-Day SMA$280.78
Analyst Price Target$342.37
Next EarningsNov 5, 2026
As of Oct 21, 2026 · Market close

CICigna Corporation

Healthcare / Medical - Healthcare Plans

Relative Leader / Watch

Strong Relative Position

NeutralEdge 8/10
$304.37−$2.23 (−0.73%)

Latest quote

  • Momentum
    84
  • Value
    72
  • Quality
    39
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Oct 21, 2026

CI Stock Analysis Summary

Cigna Corporation (CI) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 84/100. Quality is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Oct 21, 2026 · Market-close data
AIQ Composite Posture: Mixed

In a neutral regime, CI has AIQ Score of 62/100 with Momentum base of 84/100 and fading Quality at 39/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (84/100) leads while Quality (39/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.73% stock move · CI classified in Medical - Healthcare Plans.

Current Evidence

NeutralCI is in a neutral AIQ regime; Momentum is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is CI Bullish or Bearish Right Now?

CI currently has a neutral overall setup. Momentum is the strongest factor at 84/100, while Quality is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 84/100.
  • - Price is +8.54% above its 50-day SMA.
  • - Analyst target implies +12.48% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 8).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

CI's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 1 neutral, and 8 sell votes. CI's 14-day RSI is 86.07, which places the stock in an overbought momentum range. CI's beta is 0.32, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in CI?

The largest recent change in CI is Momentum moving down by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-1.0
Quality
+0.0
Risk
+0.0

What Would Change the CI Outlook?

The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

CI Decision Framework

Public evidence layers, setup checks, and risk context for Cigna Corporation.

Cigna Corporation (CI) Stock Analysis

Cigna Corporation has an AIQ Score of 62/100 in a Neutral regime. Momentum is strongest at 84/100. Beta is 0.3, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextCI is in a Neutral AIQ regime with score 62/100.
Signal ConflictThe primary conflict is that momentum leads at 84/100 while quality lags at 39/100.
Factor EvidenceMomentum 84/100 · Value 72/100 · Quality 39/100 · Risk 51/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 84/100.

TimingPass

Momentum is 84/100 and RSI (14) is 86.1.

Regime fitWait

CI is in a Neutral regime at 62/100.

Risk controlWait

Risk factor is 51/100 with beta 0.3 and annual volatility 32.37%.

ConflictWait

Current conflict: momentum leads at 84/100 while quality lags at 39/100.

AIQ Score
62/100
Price
$304.37
Beta
0.3
RSI (14)
86.1

CI Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

CI Fundamentals

CI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$71.67B
Net income
$1.66B
Free cash flow
-$718M
View full CI fundamental analysis

CI Technical Analysis

CI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
86.07
Price vs SMA-50
+8.54%
View full CI technical analysis

CI Stock Catalysts

Track CI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Nov 5, 2026
Analyst target
$342.37
News items
5
View CI earnings and stock catalysts

CI Dividend Analysis

CI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
2.03%
Annual dividend
$6.19
Payout ratio
25.31%
View CI dividend history and analysis

CI Financial Data

CI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$71.67B
EPS
$6.29
Periods
3
View CI financials

CI Risk Analysis

CI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.32
Risk score
51/100
1Y volatility
32.37%
View CI risk analysis

CI Stock News

CI stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Oct 21, 2026
Sentiment
—
Read CI stock news

CI vs Healthcare Services / Managed Care Peers

Current peer cohort: CI · CLOV · CNC · COR · CVS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
CI
Current stock
62/10072/10084/10051/1000.0232.37%Current
CLOV
Clover Health
48/10042/10076/10032/1001.0165.81%CI vs CLOV
CNC
Centene
53/10053/10080/10060/1001.647.34%CI vs CNC
COR
Cencora
62/10062/10087/10060/1000.1631.19%CI vs COR
CVS
CVS Health
58/10070/10082/10052/1000.4331.53%CI vs CVS
Pairwise Compare links: CLOV · CNC · COR · CVSCI vs CLOVCI vs CNCCI vs CORCI vs CVSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Oct 21, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a CI stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

3 recent quarterly periods are available for review.

Checked Oct 22, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
11.67
As of Oct 21, 2026
Revenue growth
—
Gross margin
11.66%
Current debt / equity
0.75
Latest quarterly evidence

Latest period Jun 30, 2026.

Review fundamentals
Quarter revenue
$71.67B
Quarter net income
$1.66B
Quarter free cash flow
-$718M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
86.07
MACD
5.11

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
51/100
Beta
0.3
Annual volatility
32.37%
Max drawdown
-20.75%

CI Stock FAQ

What is CI stock price today?

Cigna Corporation's current stock price is $304.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is CI bullish or bearish right now?

CI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is CI's market cap?

CI's market cap is $74.8B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is CI's current P/E ratio?

CI's current P/E ratio is 11.67 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is CI's RSI?

CI's 14-day RSI is 86.07 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is CI above its 50-day and 200-day moving averages?

CI is 8.54% from its 50-day SMA and 8.40% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is CI's next earnings date?

CI's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does CI pay a dividend?

CI's dividend yield is 2.17% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.